EudraVigilance is the European system for the electronic collection, management and evaluation of suspected adverse drug reaction reports. It enables the exchange of individual case safety reports between the EMA, national authorities, marketing authorisation holders and sponsors of clinical trials in the European Economic Area. The system supports the early detection and assessment of potential safety signals.
Purpose and stakeholders
The system supports the safe and effective use of medicinal products by bringing together safety-relevant information from different stakeholders. Marketing authorisation holders electronically report suspected cases for authorised medicinal products; sponsors of clinical trials use EudraVigilance as part of clinical safety reporting. National competent authorities and the EMA can use the data for regulatory oversight, signal detection and scientific assessment.
The focus is on Individual Case Safety Reports (ICSRs). An ICSR is a structured single-case report of a suspected adverse reaction. EudraVigilance processes such reports and related messages in accordance with international data standards. The database is therefore more than a technical transmission channel: it provides information for search, follow-up, signal management and regulatory decision-making.
Reporting, exchange and use of data
Electronic reporting is mandatory for marketing authorisation holders and sponsors where the applicable legal provisions require it. The EudraVigilance Gateway supports the secure exchange of standardised safety messages. Implementing Regulation (EU) No 520/2012 supplements the legal framework, including provisions on electronic reporting, data formats and technical cooperation within the pharmacovigilance system.
A report does not automatically imply causality or a regulatory action. Suspected cases are assessed together with additional data, such as clinical information, literature, epidemiological data and findings from studies. Data quality remains critical: completeness, correct coding, follow-up and timely submission determine whether a report can be meaningfully used for signal assessment.
Technical standardisation supports comparability and further processing of safety information. It facilitates automated processing, but it does not replace medical assessment. Before submission, case information must be reviewed, duplicates identified, follow-up information consolidated and medically relevant details coded consistently. A large volume of data is only useful if reports are sufficiently complete and traceable.
EudraVigilance also supports transparency, as aggregated information on reported suspected cases can be made publicly available. These data are not incidence figures and, without further assessment, do not allow conclusions about individual risk or causality. For regulatory authorities, they are a starting point for signal detection. Subsequent assessment takes into account the quality of the reports and the overall state of scientific evidence.
Access to the system and use of its functions are organised by role. Companies and sponsors must therefore define who creates reports, provides medical sign-off, submits them and processes feedback. Even if individual technical tasks are delegated, content quality and regulatory responsibility cannot be delegated. Clear roles, traceable work instructions and aligned data reconciliations are the basis for robust electronic safety reporting.
Establishing this governance begins before the first case: training, access rights and escalation pathways must be defined before enrolling participants and reviewed regularly.
This ensures that electronic reporting remains controllable even when staff change.
Ongoing quality control also includes checking data plausibility, handling queries and documenting the correction of identified errors.
Distinction from a company’s own pharmacovigilance system
EudraVigilance is a European database and reporting route. It is not a company’s pharmacovigilance system. The marketing authorisation holder still requires its own processes, staff, quality management, databases or interfaces to ensure end-to-end handling of safety information. The pharmacovigilance system master file describes this company-specific system, not EudraVigilance itself.
The existing neighbouring entry “safety database” refers to a general term. EudraVigilance, by contrast, is a specifically regulated EU system with defined stakeholders and functions. Companies must therefore not confuse technical use of the platform with transferring their legal responsibility for assessment, reporting and risk management.
Relevance for clinical trials
Even during a clinical trial, serious safety information must be captured in a structured manner, medically assessed and routed through the correct reporting pathway. Data management, the safety database, medical monitoring and regulatory affairs require aligned processes so that cases can be coded consistently, reconciled and submitted electronically. Interface errors lead to incomplete reports, delayed follow-up queries or inconsistent data sets.
Full-service CROs such as Mediconomics provide support with safety management plans, the setup and validation of data flows, ICSR case processing, medical assessment and regulatory reporting. Additional services include data reconciliations between clinical systems, safety databases and medical writing, as well as preparation for audits and inspections.
Frequently Asked Questions (FAQ)
Does EudraVigilance store only post-authorisation reports?
No. The system also supports the electronic exchange of safety reports from clinical trials in the European Economic Area.
Does an ICSR prove that a medicinal product caused an adverse reaction?
No. An ICSR documents a suspected case. Assessing a possible relationship requires additional information and scientific evaluation.
Does EudraVigilance replace an in-house safety database?
No. EudraVigilance is the EU system for exchange and analysis; marketing authorisation holders remain responsible for their own pharmacovigilance system and their legal obligations.
Regulatory References
- Directive 2001/83/EC, Title IX – establishes the EU legal framework for pharmacovigilance.
- Implementing Regulation (EU) No 520/2012 – specifies electronic pharmacovigilance activities.
- EMA, EudraVigilance – describes stakeholders, ICSR exchange and system functions.
